Maternal serum analyte screening for fetal aneuploidy

Area of Science:

• Biochemistry
• Genetics
• Obstetrics

Background:

• Maternal serum screening involves measuring biochemical markers produced by the fetoplacental unit.
• These markers are used in the first and second trimesters to assess the risk of fetal chromosomal abnormalities.

Purpose of the Study:

• To evaluate the utility of fetoplacental unit-produced chemicals as biomarkers for assessing fetal abnormality risks.
• To determine the consistency of associations between biomarker levels and chromosomal abnormalities like Down syndrome.

Main Methods:

• Measurement of specific biochemical markers in maternal serum during the first and second trimesters.
• Statistical analysis to establish associations between biomarker levels and the risk of fetal chromosomal abnormalities.

Main Results:

• Consistent associations were observed between specific protein levels and chromosomal abnormalities.
• These associations allow for the calculation of individual pregnancy risks for conditions such as Down syndrome.

Conclusions:

• Biomarkers from the fetoplacental unit are valuable tools for prenatal risk assessment of fetal abnormalities.
• Risk assessment requires special consideration for multiple pregnancies and those conceived via infertility therapy.